BF
ESPR

BOK Financial’s Esperion Therapeutics ESPR Stock Holding History

BOK Financial’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,298
Closed -$88.5K – 1173
2026
Q1 		$88.5K Buy
32,298
+8,275
+34% +$26.2K ﹤0.01% 763
2025
Q4 		$88.9K Hold
24,023
– – ﹤0.01% 776
2025
Q3 		$63.7K Buy
24,023
+12,118
+102% +$23.4K ﹤0.01% 816
2025
Q2 		$11.7K Hold
11,905
– – ﹤0.01% 957
2025
Q1 		$17.1K Hold
11,905
– – ﹤0.01% 934
2024
Q4 		$27.9K Hold
11,905
– – ﹤0.01% 883
2024
Q3 		$23.3K Hold
11,905
– – ﹤0.01% 908
2024
Q2 		$26.4K Buy
+11,905
New +$28K ﹤0.01% 906
2019
Q1 		– Sell
-6,168
Closed -$284K – 915
2018
Q4 		$284K Sell
6,168
-2,892
-32% -$139K 0.01% 747
2018
Q3 		$401K Buy
+9,060
New +$416K 0.01% 727

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

BOK Financial's ESPR Position: Q2 2026 in Review

BOK Financial sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 32,298 shares — an estimated $88.5K sold.

BOK Financial first reported a position in ESPR in Q3 2018 and held it in 10 quarters. The position peaked at $401K in Q3 2018. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • BOK Financial reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • BOK Financial sold 32,298 Esperion Therapeutics shares in Q2 2026, an estimated $88.5K.
  • BOK Financial first reported a position in Esperion Therapeutics in Q3 2018 and held it in 10 quarters.
  • BOK Financial's Esperion Therapeutics position peaked at $401K in Q3 2018.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on BOK Financial's 13F filing for Q2 2026, filed 10 Aug 2026.